ProCE Banner Activity

LA CAB + RPV in People Without HIV Viral Suppression at Baseline at Ward 86: Wk 48 Results

Conference Coverage

A retrospective study found long-term HIV viral suppression at 48 weeks with LA CAB + RPV in people with HIV viremia at initiation of therapy. 

Released: March 06, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare